The anti-dementia drugs:: myth, hype or reality?

被引:1
作者
Allain, H
Bentué-Ferrer, D
机构
[1] Univ Rennes 1, Fac Med, Lab Pharmcol Expt & Clin, F-35043 Rennes, France
[2] Univ Rennes 1, Fac Med, Ctr Memoire Ressources Rech, F-35043 Rennes, France
关键词
Alzheimer's disease; cognition; dementia; drugs; inhibitors of acetylcholinesterase; pharmacology;
D O I
10.1097/00019052-200312002-00005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The neurodegenerative diseases are in need of drugs that are capable of treating their many different presentations. Some drugs have recently been developed and approved by the authorities for use in Alzheimer's disease; their beneficial effects are no longer questionable. From the discussion about what to call these drugs (anti-dementia drugs?), it is apparent that pharmacology research has veered from pursuing the myth of the fount of eternal youth back to the reality of the struggle for survival of neurons whenever they are attacked, long before the signs of dementia have developed (antiapoptotic drugs?). The neurosciences teach that there is a biology of cognition (hence a pharmacology of cognition), and that the brain is the permanent area of the confrontation between neurogenesis and apoptosis. Pharmacology has taken this new understanding on board, and has finally defined its objective as preventing the decline of the neuron as much as of cognitive performance. It remains for clinicians to confirm the authenticity of this worldwide project.
引用
收藏
页码:S23 / S27
页数:5
相关论文
共 26 条
[1]  
ALLAIN H, 1994, ENCEPHALE, V20, P725
[2]  
ALLAIN H, 1990, CLIN THER, V12, P298
[3]   Alzheimer's disease:: the pharmacological pathway [J].
Allain, H ;
Bentué-Ferrer, D ;
Tribut, O ;
Gauthier, S ;
Michel, BF ;
Drieu-La Rochelle, C .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2003, 17 (04) :419-428
[4]   Drugs and vascular dementia [J].
Allain, H ;
Bentue-Ferrer, D ;
Tribut, O ;
Pinel, JF .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2003, 16 (01) :1-6
[5]   Drug therapy of frontotemporal dementia [J].
Allain, H ;
Bentué-Ferrer, D ;
Tribut, O ;
Mérienne, M ;
Belliard, S .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2003, 18 (03) :221-225
[6]  
ALLAIN H, 2000, LETT NEUROLOGUE, V4, P38
[7]  
ALLAIN H, 2002, REV NEUROL PARIS, V158, pB35
[8]   Clinically significant drug interactions with cholinesterase inhibitors -: A guide for neurologists [J].
Bentué-Ferrer, D ;
Tribut, O ;
Polard, E ;
Allain, H .
CNS DRUGS, 2003, 17 (13) :947-963
[9]  
BENTUEFERRER D, 2001, REV GERIATR, V26, P511
[10]   Neuroprotective and symptomatological action of memantine relevant for alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action [J].
Danysz, Wojciech ;
Parsons, Chris G. ;
Moebius, Hans-Joerg ;
Stoeffler, Albrecht ;
Quack, Guenter .
NEUROTOXICITY RESEARCH, 2000, 2 (2-3) :85-97